Keyphrases
Rituximab
100%
Adverse Event Reporting
100%
Adverse Events Profile
100%
Ocrelizumab
100%
Multiple Sclerosis
18%
Reporting Odds Ratio
18%
Adverse Event Reporting System Database
18%
Confidence Interval
9%
Infusion Reaction
9%
Safety Profile
9%
Urinary Tract Infection
9%
Anti-CD20 Antibody
9%
Inflammatory Activity
9%
Pruritus
9%
B-cell Depletion
9%
Multiple Drugs
9%
Lower Limit
9%
Disproportionality Analysis
9%
Anti-B Cell Therapy
9%
Pharmacovigilance
9%
Oral Herpes
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Rituximab
100%
Ocrelizumab
100%
Infection
18%
Multiple Sclerosis
18%
Urinary Tract Infection
9%
Infusion Related Reaction
9%
Pharmacovigilance
9%
Disproportionality Analysis
9%
Ear Pruritus
9%
Neuroscience
Rituximab
100%
Ocrelizumab
100%
Multiple Sclerosis
18%
B Cell
18%
Herpes
9%